Literature DB >> 10785836

Sleep dysfunction in Parkinson's disease.

C Trenkwalder1.   

Abstract

The frequency of sleep complaints in patients with Parkinson's disease (PD) is estimated to be between 60-90% and a variety of either disease-related or secondary mechanisms and the dopaminergic treatment itself contributes to the development of different sleep disturbances. These comprise slight, fragmented sleep with increased number of arousals and awakenings, and PD-specific motor phenomena such as nocturnal immobility, rest tremor, eye-blinking, dyskinesias, and other phenomena such as periodic and nonperiodic limb movements in sleep, restless legs syndrome, fragmentary myoclonus, and respiratory dysfunction in sleep. Depression and hallucinations/psychosis further complicate the picture. The incidence of REM sleep behavior disorder (RBD) with nightmares and violent behavior is increased in PD and may occur as a preclinical disease-related symptom. A careful sleep history of patients and their partners, polysomnograms when necessary, motor and psychiatric assessments should precede individual treatment strategies, which include adjusting dopaminergic daytime treatment, benzodiazepines for RBD, reduction of anticholinergic drugs, and, if necessary, clozapine for nocturnal psychosis.

Entities:  

Mesh:

Year:  1998        PMID: 10785836

Source DB:  PubMed          Journal:  Clin Neurosci        ISSN: 1065-6766


  16 in total

1.  Nonrecognition of depression in Parkinson's disease.

Authors:  Karen E Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

2.  Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale.

Authors:  M T Pellecchia; A Antonini; U Bonuccelli; G Fabbrini; L Ferini Strambi; F Stocchi; A Battaglia; P Barone
Journal:  Neurol Sci       Date:  2011-11-03       Impact factor: 3.307

3.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 4.  Are sleep disturbances preclinical markers of Parkinson's disease?

Authors:  Altair B dos Santos; Kristi A Kohlmeier; George E Barreto
Journal:  Neurochem Res       Date:  2014-11-30       Impact factor: 3.996

Review 5.  Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease.

Authors:  Fatai Salawu; Abdulfatai Olokoba
Journal:  Oman Med J       Date:  2015-01

6.  Excessive daytime sleepiness, objective napping and 11-year risk of Parkinson's disease in older men.

Authors:  Yue Leng; Samuel M Goldman; Peggy M Cawthon; Katie L Stone; Sonia Ancoli-Israel; Kristine Yaffe
Journal:  Int J Epidemiol       Date:  2018-10-01       Impact factor: 7.196

Review 7.  Neuroimaging insights into the pathophysiology of sleep disorders.

Authors:  Martin Desseilles; Thanh Dang-Vu; Manuel Schabus; Virginie Sterpenich; Pierre Maquet; Sophie Schwartz
Journal:  Sleep       Date:  2008-06       Impact factor: 5.849

8.  Can Qigong improve non-motor symptoms in people with Parkinson's disease - A pilot randomized controlled trial?

Authors:  Sanghee Moon; Caio V M Sarmento; Michael Steinbacher; Irina V Smirnova; Yvonne Colgrove; Sue-Min Lai; Kelly E Lyons; Wen Liu
Journal:  Complement Ther Clin Pract       Date:  2020-04-02       Impact factor: 2.446

9.  Distinct Parameters in the EEG of the PLP α-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity.

Authors:  Lorenz Härtner; Tobias W M Keil; Matthias Kreuzer; Eva Maria Fritz; Gregor K Wenning; Nadia Stefanova; Thomas Fenzl
Journal:  Front Behav Neurosci       Date:  2017-01-10       Impact factor: 3.558

Review 10.  Sleep and non-motor symptoms in Parkinson's disease.

Authors:  Antonia Maass; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-01-22       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.